Amgen Inc (AMGN) Stock AnalysisAMGNAmgen Inc

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Amgen Inc is a good buy right now due to its current price of $432.49, which is well below the analyst price target of $470 from UBS. The company's strong financial performance is highlighted by a gross margin of 72.64% in Q2 2026 and a year-to-date change of +32.00%. However, the main risk is the debt to equity ratio, which stands at 490.28%, indicating high leverage that could impact financial stability.

25 analysts cover AMGN: 10 rate it Buy, 15 Hold and 0 Sell. The average price target is 363.10.